Sat. November 21, 2009
-
Seeking Alpha (blog)
November 19, 2009
Indianapolis Star
November 18, 2009
TREATING CRAVINGS AND ADDICTIONS: One of
Eli Lilly's parters in the
diabetes drug
Byetta has some interesting news on another front. ...
Wall Street Journal (blog)
November 16, 2009
Amylin sells the
diabetes drug
Byetta through an alliance with
Eli Lilly. Its shares also have yet to recover from concerns over
Byetta's safety and a ...
Minyanville.com
November 13, 2009
While the twice-daily injectible has been a blessing for the millions of patients who currently take the drug, Byetta came under fire in August 2008 when ...
Private MD
November 13, 2009
"
healthcare professionals and patients taking
Byetta should pay close attention to any signs or symptoms of kidney problems," said Dr Amy Egan of the FDA's ...
Reuters
November 11, 2009
O: Quote, Profile, Research, Stock Buzz) rival
Byetta treatment in
Germany by the end of the year. The delays facing Victoza in the all-important US
market ...
Behavioral Health Central (blog)
November 9, 2009
And execs are confident that
Byetta LAR, a once-weekly version of exenatide partnered with Amylin Pharmaceuticals Inc. and
Eli Lilly and Co., ...
Endocrine Today
November 3, 2009
The approval of exenatide (Byetta
A Sweet Life, the source for the healthy diabetic (blog)
November 3, 2009
U.S. News & World Report
November 3, 2009
From April 2005 to October 2008, the FDA received 78 reports of kidney function problems in patients taking Byetta
Reuters
November 2, 2009
Byetta
TransWorldNews (press release)
November 2, 2009
The company today announced that
the US Food and Drug Administration (FDA) has approved an expanded indication for
Byetta
Healthcare Republic
November 2, 2009
Unlike the two currently approved GLP-1 analogues liraglutide (Victoza) and exenatide (Byetta
Barron's
November 2, 2009
The deal from which Amylin will get $75 million up front came after the Food and Drug Administration approved Amylin's
diabetes drug
Byetta
Benzinga
November 2, 2009
Byetta
Xconomy
October 30, 2009
The agency now says the companies have clearance to
market exenatide (
Byetta) as a standalone therapy for
diabetes, which means doctors won't need to ...
O) said on
Friday that its
Byetta drug has won US regulatory approval for use as a stand-alone medication to improve glycemic control in adults with type 2 ...
MarketWatch
October 30, 2009
Y) reported that Phase III clinical data showed taspoglutide worked better than the popular
diabetes treatment
Byetta
Reuters
October 30, 2009
O) said on
Friday that its
Byetta
After 24 weeks of treatment, patients who had been given taspoglutide experienced a bigger decline in their blood sugar than those who had been given Byetta ...
Voice of San Diego
October 28, 2009
Xconomy has an item about a brewing controversy in
Australia that revolves around
San Diego-based Amylin's
diabetes drug
Byetta. ...
Xconomy
October 27, 2009
From
Australia comes word that
San Diego-based Amylin Pharmaceuticals' biggest drug, exenatide (
Byetta
The Australian
October 26, 2009
Eli Lilly also makes a next-generation drug for type 2
diabetes called exenatide, sold under the brand name
Byetta. While the report names exenatide only in ...
PRMinds (press release)
October 24, 2009
It has two marketed products in its portfolio, namely,
Byetta and Symlin, for the treatment of
diabetes. Amylin primarily operates in
the US and
Germany. ...
Liraglutide belongs to the same class of drugs as the
diabetes treatment
Byetta, which has also been shown to promote weight loss. ...
WebMD
October 23, 2009
Liraglutide belongs to the same class of drugs as the
diabetes treatment
Byetta, which has also been shown to promote weight loss. ...
Reuters
October 22, 2009
Amylin has developed and gained approval for two first-in-class medicines for
diabetes, SYMLINî (pramlintide acetate) injection and
Byettaî (exenatide) ...
Seeking Alpha (blog)
October 22, 2009
Last quarter we discussed underlying prescription and share of
market trends for
Cymbalta,
Alimta,
Cialis, and
Byetta. This quarter we will take a look at ...
Reuters
October 21, 2009
(numbers do not add due to rounding)
Byettaî Lilly reports in collaboration revenue its 50 percent share of
Byetta's gross margin in
the US, and in product ...
Reuters
October 20, 2009
Quarter Ended September 30, 2009 Net product sales of $192.9 million for the quarter ended September 30, 2009 include $171.1 million for Byettaî (exenatide) ...
Motley Fool
October 20, 2009
That was the same warning the FDA gave to Amylin Pharmaceuticals' Byetta that ultimately sank sales. Lacking in the warnings is context: How many would have ...
Seeking Alpha (blog)
October 19, 2009
In 2002, when Lilly (LLY) licensed
Byetta from Amylin (AMLN), it paid a total of $110M in upfront payment and equity investment for 50% of
the US rights and ...
Reuters
October 19, 2009
Amylin has developed and gained approval for two first-in-class medicines for
diabetes, SYMLINî (pramlintide acetate) injection and
Byettaî (exenatide) ...
Pharmacy News
October 15, 2009
The growth of incretin mimetics, however, would depend on the success of brands such as Byetta (exenatide) and Januvia (sitagliptin) in receiving greater ...
Trading Markets (press release)
October 14, 2009
Despite positive data, the two drugs did not offer clinical advantages over their direct competitors,
Byetta LAR (exenatide LAR; Amylin/Alkermes/
Eli Lilly) ...
Trading Markets (press release)
October 14, 2009
At the conference,
Eli Lilly failed to adequately address the potential link between
Byetta and pancreatitis, while new data for Galvus and Eucreas may lead ...
Reuters
October 13, 2009
Amylin has developed and gained approval for two first-in-class medicines for
diabetes, SYMLINî (pramlintide acetate) injection and
Byettaî (exenatide) ...
Reuters
October 13, 2009
Patient-level claims data show that between 30 to 40 percent of patients who start
Actos, Januvia or Amylin/
Eli Lilly's
Byetta receive the drugs in the ...
Diabetes Health (press release)
October 9, 2009
... Glucotrol XL, and several brands of blood glucose monitors and test strips were listed, for example, but we did not see Januvia, Symlin, or Byetta. ...
